Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jumpei Hisanaga

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Internal Medicine (Tokyo, Japan)|December 21, 2018
Dendriform Pulmonary OssificationKeisuke Anan, Jumpei Hisanaga, Kodai Kawamura, et al.
International Journal of Rheumatic Diseases|July 29, 2017
Successful multi-target therapy including rituximab and mycophenolate mofetil in anti-melanoma differentiation-associated gene 5 antibody-positive rapidly progressive interstitial lung disease with clinically amyopathic dermatomyositisJumpei Hisanaga, Takuya Kotani, Youhei Fujiki, et al.
Thoracic Cancer|November 4, 2019
Comparisons between tumor burden and other prognostic factors that influence survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitorsYoshihiko Sakata, Kodai Kawamura, Kazuya Ichikado, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Internal Medicine (Tokyo, Japan)|December 21, 2018
Dendriform Pulmonary OssificationKeisuke Anan, Jumpei Hisanaga, Kodai Kawamura, et al.
International Journal of Rheumatic Diseases|July 29, 2017
Successful multi-target therapy including rituximab and mycophenolate mofetil in anti-melanoma differentiation-associated gene 5 antibody-positive rapidly progressive interstitial lung disease with clinically amyopathic dermatomyositisJumpei Hisanaga, Takuya Kotani, Youhei Fujiki, et al.
Thoracic Cancer|November 4, 2019
Comparisons between tumor burden and other prognostic factors that influence survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitorsYoshihiko Sakata, Kodai Kawamura, Kazuya Ichikado, et al.
Pageof 1